Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.70 |
| ▸ | ALPI | P09923 | 1/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | XIAP | P98170 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | TPH1 | P17752 | 1/20 | 0.59 |
| ▸ | GRB2 | P62993 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43411 | 1.00 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL43410 | 1.00 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL366883 | 0.92 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2310526 | 0.91 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL15656470 | 0.87 | SLC7A5 (0.76) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL14233567 | 0.86 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL156189 | 0.85 | SLC7A5 (0.74) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL837014 | 0.85 | SLC7A5 (0.74) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL16581271 | 0.85 | SLC7A5 (0.74) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL485684 | 0.85 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995238-B2 | Cyclopeptide derivatives | BIOMET DEUTCHLAND GMBH (DE) | 2006-02-07 | — | — | US | claimed |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | claimed |
| US-6610826-B1 | Useful for treatment of disorders caused by implants, defects, inflammations and of osteolytic disorders such as osteoporosis, thrombosis, cardiac infarction and arteriosclerosis | MERCK PATENT DEPARTMENT (DE) | 2003-08-26 | — | — | US | claimed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | disclosed |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | disclosed |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ZEALAND PHARMA A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| US-9751837-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-09-05 | — | — | US | disclosed |
| US-9707282-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-07-18 | — | — | US | disclosed |
| US-20160102059-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20020198142-A1 | Cyclopeptide derivatives | MERCK PATENT GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | BIOMET DEUTSCHLAND GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
| CN-1282337-A | Cyclopeptide derivatives with integrin inhibitor properties | MERCK PATENT GMBH (DE) | 2001-01-31 | — | — | CN | disclosed |
| EP-1037906-A1 | CYCLOPEPTIDE DERIVATIVES WITH INTEGRIN INHIBITOR PROPERTIES | MERCK PATENT GmbH (DE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031126-A1 | CYCLOPEPTIDE DERIVATIVES WITH INTEGRIN INHIBITOR PROPERTIES | MERCK PATENT GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| CN-1202907-A | Cyclopeptide derivatives | MERCK PATENT GMBH (DE) | 1998-12-23 | — | — | CN | disclosed |
| EP-0856007-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GmbH (DE) | 1998-08-05 | — | — | EP | disclosed |
| EP-0771818-A2 | Biotin derivatives | MERCK PATENT GmbH (DE) | 1997-05-07 | — | — | EP | disclosed |
| WO-1997014716-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 2407/4885PTGS1 4496/4885ALPI 3773/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 2076/4885PTGS1 4545/4885ALPI 3864/4885 |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | SERPINC1, TFPI, F11 | SLC7A5 4712/4885PTGS1 1407/4885ALPI 2075/4885 |
| US-20020198142-A1 | Cyclopeptide derivatives | COL2A1, SRRM2, ARGLU1 | SLC7A5 2637/4885PTGS1 673/4885ALPI 3218/4885 |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | SLC7A5 2407/4885PTGS1 4496/4885ALPI 3773/4885 |
| US-20160102059-A1 | KINASE INHIBITORS | SYK, LYN, BTK | SLC7A5 4266/4885PTGS1 586/4885ALPI 742/4885 |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | SLC7A5 2407/4885PTGS1 4496/4885ALPI 3773/4885 |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 2493/4885PTGS1 4530/4885ALPI 3753/4885 |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | CORO1C, CYCS, CORO1A | SLC7A5 2879/4885PTGS1 173/4885ALPI 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.